Last reviewed · How we verify
Levalbuterol
Levalbuterol activates beta 2 -adrenergic receptors, increasing cyclic AMP and relaxing airway smooth muscles.
At a glance
| Generic name | Levalbuterol |
|---|---|
| Also known as | Xopenex HFA (levalbuterol tartrate)Inhalation Aerosol, Xopenex HCl Inhalation Solution, Xopenex, Xopenex®: 4 puffs administered 30 seconds apart, Xopenex Inhalation Solution |
| Sponsor | University of Aleppo |
| Target | beta 2 -adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Levalbuterol works by activating beta 2 -adrenergic receptors on airway smooth muscle, which increases the production of cyclic AMP. This increase leads to muscle relaxation and prevents the release of inflammatory mediators, helping to keep airways open and reduce bronchoconstriction.
Approved indications
- Acute exacerbation of asthma
- Bronchospasm
- Bronchospasm Prevention
Common side effects
- Allergic reaction
- Flu syndrome
- Accidental injury
- Pain
- Back pain
- Tachycardia
- Migraine
- Dyspepsia
- Leg cramps
- Dizziness
- Hypertonia
- Nervousness
Drug interactions
- Other short-acting sympathomimetic aerosol bronchodilators and adrenergic drugs
- Beta-blockers
- Diuretics
- Digoxin
- Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants
Key clinical trials
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (PHASE3)
- High Flow Nasal Cannula Rates in Pediatric Asthma (NA)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis (PHASE1, PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (PHASE3)
- GRANITE: Airsupra Effectiveness in the Real World
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |